Neumora Therapeutics, Inc. 8K

Neumora Therapeutics reported favorable repeat toxicology results for NMRA-215 and now plans to file an IND and start Phase 1 trials in 2026 after determining prior adverse findings were likely unrelated to the drug.

Neumora Therapeutics, Inc. announced favorable results from a repeat 13‑week rat toxicology study of its investigational NLRP3 inhibitor NMRA-215, conducted after a prior study showed unexpected adverse findings and triggered a for-cause audit that uncovered study discrepancies. In the new 162-animal study, no unexpected in-life adverse findings were observed, and together with prior 28‑day rat, 28‑day dog, and 13‑week dog studies, Neumora concluded the earlier adverse events were not related to NMRA-215. Based on this toxicology package and pre-clinical efficacy data in obesity models, the company plans to submit an IND application for NMRA-215 in the fourth quarter of 2026 and to initiate a Phase 1 clinical study by the end of 2026.

Filing Facts

CIK

1885522

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-316819

Alert Tier

6